Effect of pharmacokinetic profile on the pancreatic toxicity and efficacy of tacrolimus in rats

Takashi Mitamura, Atsushi Yamada, Kaori Hanaoka, Masayuki Asano, Toshiro Niwa, Jiro Seki
2008 Journal of Toxicological Sciences  
mg/kg/day were given once daily for 8 days in the bolus intravenous injection groups. In the continuous intravenous infusion groups, tacrolimus was infused using an Alzet ® osmotic mini-pump for 9 days at the same doses. Pancreatic insulin content decreased dose-dependently in both the bolus intravenous injection es caused by the two dosing regimens. At 0.03 mg/kg, continuous intravenous infusion did not cause glu-erance. The pharmacokinetic data indicated that continuous intravenous infusion
more » ... sulted in a sustained blood drug concentration with an area under the curve (AUC) similar to that obtained with the bolus thoraxes of recipients. Tacrolimus doses of 0.01, 0.1, or 1 mg/kg/day were administered from day 0 to day 13. Both bolus intramuscular administration and continuous intravenous infusion prolonged skin allograft groups given the same doses. To summarize, the sustained-release of tacrolimus resulted in a steady blood drug concentration with an AUC similar to that of the bolus administration. In rats, it was better tolerated tion (Cmax). These results indicate that the sustained-release formulation has the potential to improve the safety of tacrolimus.
doi:10.2131/jts.33.575 pmid:19043279 fatcat:wdzy3jqvfzgyrppeqac6jilt6e